0001209191-21-002198.txt : 20210106
0001209191-21-002198.hdr.sgml : 20210106
20210106171444
ACCESSION NUMBER: 0001209191-21-002198
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210104
FILED AS OF DATE: 20210106
DATE AS OF CHANGE: 20210106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STUELPNAGEL JOHN R
CENTRAL INDEX KEY: 0001189140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39035
FILM NUMBER: 21511634
MAIL ADDRESS:
STREET 1: 10X GENOMICS, INC.
STREET 2: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 10x Genomics, Inc.
CENTRAL INDEX KEY: 0001770787
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 455614458
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: (925) 401-7300
MAIL ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: 10X Genomics, Inc.
DATE OF NAME CHANGE: 20190315
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-04
0
0001770787
10x Genomics, Inc.
TXG
0001189140
STUELPNAGEL JOHN R
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
PLEASANTON
CA
94588
1
0
0
0
Class A Common Stock
2021-01-04
4
S
0
1300
138.9138
D
487191
D
Class A Common Stock
2021-01-04
4
S
0
5200
139.8819
D
481991
D
Class A Common Stock
2021-01-04
4
S
0
900
140.9411
D
481091
D
Class A Common Stock
2021-01-04
4
S
0
100
141.61
D
480991
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $138.33 to $139.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $139.42 to $140.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $140.60 to $141.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Eric S. Whitaker, as Attorney-in-Fact
2021-01-06